Literature DB >> 34448965

Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer.

Georgios Gemenetzis1,2, Alex B Blair1, Minako Nagai1,3, William R Burns1, Christopher L Wolfgang4, Jin He5, Vincent P Groot1,6, Ding Ding1, Ammar A Javed1, Richard A Burkhart1, Elliot K Fishman7, Ralph H Hruban8, Matthew J Weiss1,9, John L Cameron1, Amol Narang10, Daniel Laheru11, Kelly Lafaro1, Joseph M Herman12, Lei Zheng11.   

Abstract

BACKGROUND: The introduction of multi-agent chemotherapy and radiation therapy has facilitated potential resection with curative intent in selected locally advanced pancreatic cancer (LAPC) patients with excellent outcomes. Nevertheless, there remains a remarkable lack of consensus on the management of LAPC. We sought to describe the outcomes of patients with LAPC and objectively define the multidisciplinary selection process for operative exploration based on anatomical factors.
METHODS: Consecutive patients with LAPC were evaluated for pancreatic surgery in the multidisciplinary clinic of a high-volume institution, between 2013 and 2018. Prospective stratification (LAPC-1, LAPC-2, and LAPC-3), based on the involvement of regional anatomical structures, was performed at the time of presentation prior to the initiation of treatment. Resection rates and patient outcomes were evaluated and correlated with the initial anatomic stratification system.
RESULTS: Overall, 415 patients with LAPC were included in the study, of whom 84 (20%) were successfully resected, with a median overall survival of 35.3 months. The likelihood of operative exploration was associated with the pretreatment anatomic LAPC score, with a resection rate of 49% in patients classified as LAPC-1, 32% in LAPC-2, and 11% in LAPC-3 (p < 0.001). Resected patients with improvement of the LAPC score at the time of exploration had significantly longer median overall survival compared with those with no change or progression of LAPC score (60.7 vs. 29.8 months, p = 0.006).
CONCLUSIONS: Selected patients with LAPC can undergo curative-intent surgery with excellent outcomes. The proposed Johns Hopkins anatomic LAPC score provides an objective system to anticipate the probability of eventual surgical resection after induction therapy.
© 2021. Society of Surgical Oncology.

Entities:  

Mesh:

Year:  2021        PMID: 34448965      PMCID: PMC8688211          DOI: 10.1245/s10434-021-10663-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  47 in total

1.  The "artery first" approach for resection of pancreatic head cancer.

Authors:  Jürgen Weitz; Nuh Rahbari; Moritz Koch; Markus W Büchler
Journal:  J Am Coll Surg       Date:  2009-12-03       Impact factor: 6.113

2.  Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Edward P Balaban; Pamela B Mangu; Alok A Khorana; Manish A Shah; Somnath Mukherjee; Christopher H Crane; Milind M Javle; Jennifer R Eads; Peter Allen; Andrew H Ko; Anitra Engebretson; Joseph M Herman; John H Strickler; Al B Benson; Susan Urba; Nelson S Yee
Journal:  J Clin Oncol       Date:  2016-05-31       Impact factor: 44.544

3.  Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.

Authors:  Elena Rangelova; Agnes Wefer; Saga Persson; Roberto Valente; Kimitaka Tanaka; Nicola Orsini; Ralf Segersvärd; Urban Arnelo; Marco Del Chiaro
Journal:  Ann Surg       Date:  2021-03-01       Impact factor: 12.969

4.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

Authors:  Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian
Journal:  Cancer Res       Date:  2014-06-01       Impact factor: 12.701

5.  Pancreaticoduodenectomy and Superior Mesenteric Vein Resection Without Reconstruction for Locally Advanced Pancreatic Cancer.

Authors:  Bradley N Reames; Michele M Gage; Aslam Ejaz; Alex B Blair; Elliot K Fishman; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  J Gastrointest Surg       Date:  2018-01-23       Impact factor: 3.452

6.  Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.

Authors:  Eva Versteijne; Mustafa Suker; Karin Groothuis; Janine M Akkermans-Vogelaar; Marc G Besselink; Bert A Bonsing; Jeroen Buijsen; Olivier R Busch; Geert-Jan M Creemers; Ronald M van Dam; Ferry A L M Eskens; Sebastiaan Festen; Jan Willem B de Groot; Bas Groot Koerkamp; Ignace H de Hingh; Marjolein Y V Homs; Jeanin E van Hooft; Emile D Kerver; Saskia A C Luelmo; Karen J Neelis; Joost Nuyttens; Gabriel M R M Paardekooper; Gijs A Patijn; Maurice J C van der Sangen; Judith de Vos-Geelen; Johanna W Wilmink; Aeilko H Zwinderman; Cornelis J Punt; Casper H van Eijck; Geertjan van Tienhoven
Journal:  J Clin Oncol       Date:  2020-02-27       Impact factor: 44.544

Review 7.  Recent progress in pancreatic cancer.

Authors:  Christopher L Wolfgang; Joseph M Herman; Daniel A Laheru; Alison P Klein; Michael A Erdek; Elliot K Fishman; Ralph H Hruban
Journal:  CA Cancer J Clin       Date:  2013-07-15       Impact factor: 508.702

8.  Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection.

Authors:  Georgios Gemenetzis; Vincent P Groot; Alex B Blair; Daniel A Laheru; Lei Zheng; Amol K Narang; Elliot K Fishman; Ralph H Hruban; Jun Yu; Richard A Burkhart; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  Ann Surg       Date:  2019-08       Impact factor: 12.969

9.  Management of Locally Advanced Pancreatic Cancer: Results of an International Survey of Current Practice.

Authors:  Bradley N Reames; Alex B Blair; Robert W Krell; Vincent P Groot; Georgios Gemenetzis; James C Padussis; Sarah P Thayer; Massimo Falconi; Christopher L Wolfgang; Matthew J Weiss; Chandrakanth Are; Jin He
Journal:  Ann Surg       Date:  2021-06-01       Impact factor: 13.787

10.  Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?

Authors:  Jin He; Alex B Blair; Vincent P Groot; Ammar A Javed; Richard A Burkhart; Georgios Gemenetzis; Ralph H Hruban; Kevin M Waters; Justin Poling; Lei Zheng; Daniel Laheru; Joseph M Herman; Martin A Makary; Matthew J Weiss; John L Cameron; Christopher L Wolfgang
Journal:  Ann Surg       Date:  2018-07       Impact factor: 13.787

View more
  3 in total

1.  The Role of Diffusion-Weighted Magnetic Resonance Imaging in Staging after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma.

Authors:  Edoardo Maria Muttillo; Emanuele Felli
Journal:  Ann Surg Oncol       Date:  2022-04-11       Impact factor: 5.344

2.  Added value of 3T MRI and the MRI-halo sign in assessing resectability of locally advanced pancreatic cancer following induction chemotherapy (IMAGE-MRI): prospective pilot study.

Authors:  Thomas F Stoop; Eran van Veldhuisen; L Bengt van Rijssen; Remy Klaassen; Oliver J Gurney-Champion; Ignace H de Hingh; Olivier R Busch; Hanneke W M van Laarhoven; Krijn P van Lienden; Jaap Stoker; Johanna W Wilmink; C Yung Nio; Aart J Nederveen; Marc R W Engelbrecht; Marc G Besselink
Journal:  Langenbecks Arch Surg       Date:  2022-10-15       Impact factor: 2.895

3.  Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer.

Authors:  M R Tomaszewski; K Latifi; E Boyer; R F Palm; I El Naqa; E G Moros; S E Hoffe; S A Rosenberg; J M Frakes; R J Gillies
Journal:  Radiat Oncol       Date:  2021-12-15       Impact factor: 3.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.